TD Cowen initiated coverage of Celldex with an Outperform rating and no price target. Celldex’s lead asset, barzolvolimab, addresses a significant unmet need in chronic urticaria, or CU, and has “blockbuster potential” in that indication and chronic inducible urticaria, or CIndU, the analyst tells investors. Success in other mast-cell driven diseases, like prurigo nodularis and eosinophilic esophagitis, could provide “meaningful upside,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CLDX:
- Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
- Celldex upgraded to Equal Weight from Underweight at Wells Fargo
- Biotech Alert: Searches spiking for these stocks today
- Celldex 7.43M share Spot Secondary priced at $27.00
- Celldex Therapeutics Announces Pricing of Public Offering of Common Stock